BriaCell CEO Letter to Shareholders

Repeated positive recommendation from Data Safety Monitoring Board (“DSMB”) of pivotal Phase 3 study for lead clinical candidate Bria-IMT™ in combination with checkpoint inhibitorBria-IMT has received Fast Track designation from FDA and patient enrollment has been accelerating in the pivotal Phase 3 study in metastatic breast cancerSuccessful completion of the pivotal study may lead to a Biologics License Application submission, Priority Review, Full Approval, and commercializationInterim analysis planned a ...